Stock Groups

Merck KGaA predicts more earnings gains on lab supplies demand -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – A Merck KGaA logo is pictured in Darmstadt (Germany), January 28, 2016. REUTERS/Ralph Orlowski

FRANKFURT, (Reuters) – Germany’s Merck KGaA stated it expects strong earnings growth in the coming year. This is mainly due to its Life Science unit which supplies material and equipment to COVID-19-vaccine makers as well as to a buoyant industry of pharmaceuticals.

On Thursday, the diversified group announced that they expect strong sales growth without the impact of currency swings.

The company also produces speciality chemicals, pharmaceuticals and said that Life Science will likely be the main growth driver.

In line with a consensus of analysts posted by Merck, the adjusted EBITDA rose 17.3% to 6.1 billion euros ($6.77 trillion) in 2021.

($1 = 0.9007 euros)

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, futures, indexes and Forex. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]